Health care stocks were mixed premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was down a slight 0.2% and the iShares Biotechnology ETF (IBB) was recently inactive.
Humana (HUM) shares rose nearly 3% after the company reported an increase in Q4 revenue and issued a 2025 revenue outlook above analysts' expectations.
Biohaven (BHVN) shares advanced by over 7% after the company said the Food and Drug Administration accepted for priority review its new drug application for troriluzole to treat adult patients with spinocerebellar ataxia.
Royalty Pharma (RPRX) shares were down more than 0.4% after the company reported lower Q4 net income and revenue.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。